|
 Biotechnology
News
Betting
on biotech (San Diego Union-Tribune)
Booming industry remains a huge gamble for investors.
California's
Stem Cell Bid Stuck in Neutral (Los Angeles Times)
When California voters signed off on a $3-billion investment in
embryonic stem cell research last fall, the state seemed poised
on the scientific cutting edge, armed with the money to circumvent
White House policy viewed by many as holding the U.S. back.
Stem
cell panel picks S.F. (San Francisco Chronicle)
Tally of points after weekend site visits gives city clear edge
for Friday's full-committee vote.
Careful
How You Monkey With DNA (Wired)
The laboratory creation of chimeras -- animals with mixed-species
heritage -- has become so advanced that scientists have drawn up
regulations to prevent the production of creatures that blur the
line between animal and human.
State's
biotech industry is tops (San Francisco Chronicle)
California hasn't lost its edge in biotech despite raids by other
states eager to lure away its high-paying jobs, a report on the
state's biotech industry concluded.
Some
in Biotech Prefer an Acquisition to an I.P.O. (New York Times)
Starting a company and taking it public has long been the goal of
many biotechnology entrepreneurs and the venture capitalists that
back them.
Industry
invests in students -- its future workers (Boston Globe)
Erin Bengiovanni's high school biology students still dissect frogs.
Now they also dissect DNA.
Cells
That Go Back in Time (Wired)
Lop off a newt's leg or tail, and it will grow a new one. The creature's
cells can regenerate thanks to built-in time machines that revert
cells to early versions of themselves in a process called dedifferentiation.
Biolaser
Lights Up Stem Cells (Wired)
Scientists have developed a laser that could illuminate stem cells
in greater detail than ever, revealing the important steps they
take to become neuron, heart or other types of cells.
Pfizer’s
profit prescription (Red Herring)
Pfizer draws criticism with plan to market a promising cholesterol
drug only in combination with Lipitor.
Stem
Cells Goose Xenotransplants (Wired)
Israeli scientists are using stem cells from pig embryos to grow
replacement organs for transplantation. The organs have grown and
functioned well in mice -- is it only a matter of time before people
are walking around with pig organs?
Biogen:
How Deep a Wound Is Tysabri? (BusinessWeek)
Though the withdrawal of its multiple sclerosis drug hurts the biotech
giant less than its partner, Elan, its stock remains vulnerable.
Stem
cell chief key to site pick (Silicon Valley/San Jose Business
Journal)
San Jose's quest to land the headquarters for the new California
Institute for Regenerative Medicine, the agency charged with disbursing
$3 billion in state money for stem-cell research, might best be
served by persuading the site-selection committee that the city
is home to the largest pool of the best scientific minds in the
country -- perhaps even the world -- and that the ideal candidate
to lead the institute can be found right here.
With
money flowing, happy days are here again for biotech firms (Baltimore
Business Journal)
Biotech is hot and the industry is maturing. New products, new alliances
and new financing structures are beginning to produce more consistent,
sustainable growth in this historically volatile industry.
California
stem-cell funding spawns wannabes (San Francisco Business Times)
As California implements its $3 billion stem-cell proposition, other
states are pushing forward with research funding plans of their
own for fear of missing out on a financial bonanza.
Eyes
on the prize (San Diego Union-Tribune)
Hoping to get a big chunk of the state's stem cell funding, San
Diego focuses on attracting top-notch researchers.
Scripps
to handle spinoffs out west (St. Petersburg Times)
The role of turning inventions into viable businesses will remain
in California, the institute's president says.
Go
to Biotechnology News Archive
|
